Innate immune complement activation may contribute to sickle cell disease (SCD) pathogenesis.
| INTRODUCTION
The pathophysiology of sickle cell disease (SCD) includes anemia, oxidative stress, hemolysis, inflammation and vaso-occlusion. 1 Inflammatory vascular episodes are a hallmark of SCD. Red cell, platelet and leukocyte activation and aggregation, together with activation of endothelial cell adhesion molecules such as P-selectin mediate vascular occlusion and the consequent organ damage that is characteristic of SCD. 2 Ischemia-reperfusion physiology underpins SCD biology when vessels are transiently occluded in organs throughout the body and subsequently reopened. 3, 4 In this ischemia-reperfusion paradigm, the innate immune system plays a key role in promoting the inflammatory response, which includes TLR4 signaling and complement activation. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] The first report that complement activation may be involved in SCD was published in 1967 by Francis and Womack. 15 Since then, many studies have reported increased levels of complement-derived fragments in the blood of SCD patients, demonstrating that complement is activated in SCD and suggesting that complement may play an important role in the pathophysiology of the disease. [9] [10] [11] [12] [13] 16 Several studies suggested that complement activation takes place through the alternative pathway, which would be triggered by the membrane phospholipid changes that occur in SS red blood cells (RBCs). 10, 11 Moreover, recent investigations have suggested that alternative pathway activation may be increased by a high blood concentration of phosphatidylserine-rich microparticles as may occur in SCD; alternative pathway activation can also be demonstrated in stored RBCs and
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this pathway is activated due to heme released by lysed RBCs. 11, 14, [17] [18] [19] [20] [21] Therefore, these studies of SCD patients showing evidence of complement activation suggest that complement, another major component of innate immunity, may play a fundamental role in the pathophysiology of SCD.
Despite these many investigations demonstrating that complement activation occurs in SCD patients, few studies have addressed the question as to whether complement plays any role in the severe clinical manifestations of SCD, especially vaso-occlusion and tissue injury that lead to substantial patient suffering and early mortality. Several complementderived fragments, most prominently C5a, are known to activate the cells involved in SCD that mediate inflammation, pain, and vascular occlusion, including leukocytes, platelets, mast cells and endothelial cells. 2, [22] [23] [24] In this study, we used Townes-SS mice, a well-defined model of SCD 25 to investigate whether hypoxia/reoxygenation (H/R), a mimic of ischemia-reperfusion physiology, activates complement and whether C5a induces P-selectin mediated vaso-occlusion. Our study demonstrates that C5a plays a fundamental role in inflammation, cell activation, and vaso-occlusion.
| METHODS

| Mice
All animal experiments were approved by the University of Minnesota's Institutional Animal Care and Use Committee. These studies utilized male and female Townes-SS mice on a 129/B6 mixed genetic background. 25 The SS mice were created by knocking in human α and A γβ S globins into the deletion sites for murine α-globin and β-globin. bins with a half-life of 11.5 days. 26 All animals were housed in specific pathogen-free rooms to limit infections and kept on a 12 hour (h) light/dark cycle at 21°C. All animals were monitored daily including weekends and holidays for health problems, food and water levels and cage conditions. Littermates were randomly assigned to different treatment groups. All animals were included in each endpoint analysis and there were no unexpected adverse events that required modification of the protocol. Mice were aged 8-14 weeks.
| Immunofluorescence staining of tissues
Townes-SS and AA mice were exposed to H/R with 1 hour in hypoxia (7% O 2 /93% N 2 ) followed by 1 hour in room air before tissue collection.
Control SS and AA mice not exposed to hypoxia before tissue collection.
Alternatively, SS and AA mice were infused with vehicle (saline) or recombinant mouse complement fragment C5a (R&D Systems#2150-C5) before tissue collection. Kidneys, livers, lungs and dorsal skin were collected 30 minutes after infusion and placed in optimal cutting temperature (OCT) compound, snap-frozen in liquid N 2 and stored at -85°C prior to frozen sectioning in a microtome-cryostat into 6 μm (kidneys, livers, lungs) or 60 μm (skin) sections. Tissues collected from mice exposed to H/R and their room air controls were stained with primary antibodies to C3 activation fragments C3b/iC3b/C3c (Hycult #HM1065), C5b-9 (Abcam #ab55811) and endothelial cell marker CD31 (Abcam #ab119341 were counted from 3 independent image fields collected from each mouse organ (n = 3) for a total of 9 independent fields used for each condition. Results are expressed as mean percent ± SD.
| Measurement of vaso-occlusion (microvascular stasis)
Townes-SS and AA mice were anesthetized with a mixture of ketamine (106 mg/kg) and xylazine (7.2 mg/kg) and implanted with dorsal skin-fold chambers. After implantation, mice were placed on an intravital microscopy stage and 20-24 flowing subcutaneous venules in the chamber window were selected and mapped as previously described. 27 After baseline selection of flowing venules, mice were infused with zymosan-treated mouse serum, zymosan-treated heat-inactivated serum, recombinant murine C5a (R&D Systems#2150-C5) or vehicle (saline). Alternatively, mice were exposed to H/R (7% O 2 /93% N 2 for 1 hour followed by room air 
| Immunoblots
Microsomes and nuclear extracts were isolated from tissues of mice as previously described. 28 Immunoblots of cellular subfractions ( (GE Healthcare) and a Typhoon FLA 9500 imager (GE Healthcare).
| Statistics
Analyses were performed with SigmaStat 3.5 for Windows (Systat Software, San Jose, CA). Comparisons of two treatment groups were made using an unpaired Student's t-test. Comparisons of three or more treatment groups were made using one-way analysis of variance using the Holm-Sidak method.
3 | RESULTS
| H/R induces complement activation
Ischemia-reperfusion physiology occurs in SCD with cycles of vasoocclusion and reperfusion that can activate complement. We first investigated whether H/R induced complement activation and deposition in organs. We found that kidneys, livers and lungs of SS mice had significantly increased levels of C3 activation fragments and C5b-9
following H/R ( Figure 1A -C, Supporting Information Figures S1-3 and
Supporting Information Tables S1-6 ). In kidneys, control untreated SS mice had significantly more C3 activation fragments and C5b-9 Tables S1-2 [Quantification]). Deposition of C3 fragments and C5b-9 increased significantly in AA and SS kidneys after H/R with SS + H/R being significantly higher than AA+H/R. In the kidney, C3 fragments were localized primarily on glomeruli and C5b-9 complexes were localized primarily around tubules.
In livers, control untreated SS mice appeared to have slightly higher levels of C3 activation fragments and C5b-9 deposition ( Figure 1B [60X2Z], Supporting Information Figure S2 [20X]), but these differences were not significant (Supporting Information   Tables S3-4 [Quantification]). Deposition of C3 fragments and C5b-9
increased significantly in the livers of SS mice after H/R with SS + H/R being significantly higher than AA+H/R. In the livers of AA mice, C5b-9 complexes, but not C3 fragments, were significantly higher after H/R. In the liver, C3 fragments and C5b-9 complexes were localized around hepatic sinusoids and blood vessels.
In lungs, C3 activation fragments were similar in control untreated AA and SS mice. But C5b-9 deposition was greater in control SS mice compared to control AA mice ( Figure 1C [60X], Supporting Information sickling (Supporting Information Figure S4 ). RBCs collected from an AA mouse had 0% sickling in normoxia and 5% after hypoxia.
Complement factor B, is a component of the alternative pathway that circulates in the blood as a single chain polypeptide. Upon activation of the alternative pathway, it is cleaved by factor D yielding the noncatalytic fragment Ba and the catalytic fragment Bb. 29 We asked
whether Bb was demonstrable in plasma. Immunoblots of plasma Bb Complement is activated after hypoxia-reoxygenation. AA and SS mice (n = 3/group) were exposed to 1 hour of hypoxia (7% O 2 /93% N 2 ) followed by 1 hour of reoxygenation in room air (H/R). Control AA and SS mice were in room air. Organs were harvested, frozen in OCT compound, sectioned and immunostained for C3 activation fragments (C3b/iC3b/C3c) (red), C5b-9 (green) and endothelial cell marker CD31 (blue) showed more Bb in SS mice compared to AA mice and the Bb level was greatly increased in SS mice post-H/R ( Figure 1D ). However, plasma C5a levels were similar in AA and SS mice in normoxia and after 5, 15 or 30 minutes of H/R (Supporting Information Figure S5A -B). We hypothesize that C5a might be generated locally on cell membranes by H/R and cleared rapidly by C5a receptors on cells without increasing C5a levels in the plasma.
| C5a causes microvascular stasis (vaso-occlusion) in SS mice
Since H/R activates complement, we investigated whether complement activation products such as C5a would promote vaso-occlusion. We have previously shown that H/R triggers vaso-occlusion in sickle mice but not in normal control mice. 27 We first tested the effect of mouse serum containing complement that was activated with zymosan, a strong, complement activator. 30 We found that zymosan-activated mouse serum induced vasoocclusion in SS mice, but not in SS mice infused with complement-inactive, zymosan-treated serum (heat-inactivated) ( Figure 2A ). This experiment suggests that a complement factor derived from complement activation may promote vaso-occlusion in SS mice.
Since C5a is the most active complement-derived fragment that stimulates multiple vascular responses, including leukocyte, platelet and endothelial cell activation, we investigated whether C5a infused in SS mice would promote vaso-occlusion. As shown in Figure 2B , C5a induced microvascular stasis in SS mice but not in AA mice, an effect of C5a that was blocked by pre-treatment of the SS mice with an antibody against C5aR ( Figure 2C ).
| C5a induces hepatic pro-inflammatory responses in SS mice that are blocked by anti-C5aR
In previous studies, we have shown that H/R induces hepatic proinflammatory, pro-adhesive responses that are required for induction of microvascular stasis in SS mice. 27, [31] [32] [33] We investigated whether 3.4 | C5a induces expression of P-selectin and vWF on HUVEC in culture and on vascular endothelium in SS and AA mice
The P-selectin adhesion molecule has been shown to be very important in the mechanism of vaso-occlusion in SCD. [34] [35] [36] [37] Previous studies demonstrated that C5a induces P-selectin and vWF on endothelial cells in culture. 38 As already noted above, an antibody to C5aR
blocked stasis, therefore we tested whether an antibody against C5aR In lungs, control untreated SS mice had significantly more P-selectin and vWF expression on the vessel wall than control AA mice ( Figure 3D [120X], Supporting Information Figure S9 [20X] and Supporting Information Tables S11-12 [Quantification]). P-selectin and vWF expression on lung vessel walls increased significantly in AA and SS mice after C5a infusion with SS + C5a being significantly higher than AA+C5a. In the lungs, P-selectin and vWF were seen primarily co-localized on blood vessels.
In dorsal skin, control untreated SS mice had significantly more P-selectin and vWF expression in the vessels than control AA mice ( Figure 3E [120X], Supporting Information Figure S10 [20X] and Supporting Information Tables S13-14 [Quantification]). P-selectin and vWF expression in skin vessels increased significantly in SS mice, but not AA mice, after C5a infusion with SS + C5a being significantly higher than AA+C5a. P-selectin and vWF were co-localized primarily with endothelial cell CD31 on the vessel wall.
We found little or no platelet CD41 staining in kidneys, livers or lungs (Supporting Information Figure S11A ). However, some platelet CD41 staining could be seen in the skin blood vessels (Supporting Information Figure S11B ). We saw no co-localization of P-selectin or vWF with platelet CD41 in any of the tissues. P-selectin and vWF were primarily colocalized with CD31. This is consistent with C5a activating P-selectin and vWF expression primarily on endothelial cells of the vessel wall.
| P-selectin blockade inhibits microvascular stasis induced by C5a in SS mice
Since C5a promotes vaso-occlusion and the expression of endothelial P-selectin, we asked whether blocking P-selectin would interfere with C5a-induced vaso-occlusion. As shown in Figure 4A , a blocking antibody against P-selectin, but not an IgG control, given before infusion of C5a abolished the development of microvascular stasis. This experiment demonstrates that P-selectin is a key mediator of C5a-induced vaso-occlusion.
3.6 | Anti-C5 or anti-C5aR IgG inhibit vaso-occlusion induced by H/R
Since both H/R and C5a induce microvascular stasis and H/R activates complement, we tested whether inhibition of C5 cleavage or blockade of C5aR would reduce H/R-induced stasis. As shown in Figure 4B , IgG antibodies against C5 or C5aR significantly inhibited the development of microvascular stasis at 1 and 4 hour after H/R compared to IgG controls (P < 0.01). Thus, these results clearly demonstrate the critical role of C5a, through P-selectin induction, in H/Rinduced vaso-occlusion in the Townes-SS mouse model of SCD.
| DISCUSSION
In these studies, we have demonstrated that complement plays a major role in the tissue injury of SCD focusing on ischemia-reperfusion, which is at the center of the pathophysiology of this condition.
We elicited ischemia-reperfusion through the well-established, clinically relevant H/R model. First, we found that H/R causes complement activation and tissue deposition of C3 fragments and the membrane attack complex (MAC or C5b-9). As in other forms of ischemia-reperfusion, complement activation by H/R may begin through recognition molecules of the lectin pathway such as mannose binding protein, followed by activation of MASP1/MASP2, C4/C2, or C2 alone, and the alternative pathway. 29, [39] [40] [41] [42] Then, complement activation proceeds, yielding the main mediator of ischemia-reperfusion, C5a and also C5b-9 (MAC).
Without inducing H/R, we found increased plasma levels of Bb, a fragment of complement factor B, in SS mice relative to AA mice, indicating alternative pathway involvement. 11 This suggests intermittent vaso-occlusion and ongoing ischemia-reperfusion pathophysiology in SS mice, since we found that exposure to H/R further increased Bb in the plasma of SS mice but not AA mice. Another contribution to increased Bb in SS mice that have not been subjected to H/R may be related to direct, ongoing, alternative pathway activation by RBCs, as discussed below. It is possible that the initiation of complement activation in H/R is through the lectin pathway. 39, 40, 42 This requires additional studies because of its potential clinical relevance to define a possible therapeutic site to interfere with the effects of ischemiareperfusion in SCD patients.
Given the prominent role of C5a in inflammation and its wellknown action as the effector molecule of ischemia-reperfusion, 40 our current studies focused on C5a. We demonstrated that C5a in zymosan-activated serum or C5a itself given to SS mice induced venous occlusion, an effect that is C5aR-dependent. We also found that Townes-SS mice demonstrate a C5a-dependent promotion of inflammation through activation of NF-κB and increased expression of TLR4. Our finding that C5a activates TLR4 expression in the context of H/R suggests that cross-talk between complement and TLR4 may be a convergence point of native immunity in SCD since
we and others have previously demonstrated a key role for TLR4 in SCD pathophysiology. [5] [6] [7] [43] [44] [45] Like TLR4, the complement system also contributes to SCD pathogenesis, in part due to ischemiareperfusion pathophysiology.
Importantly, we also found that C5a increased the expression of the adhesion molecules VCAM-1, ICAM-1 and E-selectin in SS mice. This report demonstrated that a monoclonal antibody against P-selectin reduces vaso-occlusive crises in SCD patients. 37 Therefore, we first confirmed the ability of C5a to activate P-selectin expression in vitro 38 and then demonstrated in vivo that C5a also induces P-selectin-mediated vaso-occlusion in SS mice. As shown in Figure 4A , anti-P-selectin IgG, but not isotype control IgG, markedly inhibits C5a-induced vascular stasis in SS mice. Finally, the anti-mouse C5 antibody BB5.1 as well as an anti-C5aR antibody could block H/R-induced stasis as shown in Figure 4B . Therefore, our current study demonstrates a central role of complement activation triggered by H/R in SS mice and its pathogenic role in vaso-occlusion through C5a in activation of inflammatory mechanisms. We propose that this form of complement activation plays a major role in the pathogenesis of patients with SCD over their lifespan, since they undergo multiple severe crises triggered by episodes of ischemia-reperfusion, often of an H/R nature.
With regard to the clinical import of our study, it is essential to consider that complement may also be activated in SCD through a different mechanism from the one we report here. This other mechanism could be initiated by direct activation of the alternative pathway by 
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Another potential mechanism of complement activation in SCD is that phosphatidylserine molecules on the surface of SS-RBCs and activated platelets are able to induce the assembly of prothrombin in complexes that lead to thrombin generation, which could generate biologically active C3 and C5 fragments, including C3a and C5a. 20, 47 In addition, SS-RBCs might be more susceptible to complement activation through reduced CD55 and CD59 expression. anti-C5 antibody eculizumab has been beneficial in SCD patients with delayed transfusion reactions and hyperhemolysis. 49 These data suggest that an anti-C5 antibody may be beneficial in certain other patients with SCD. In recommending this approach, we temper our enthusiasm due to the potential attendant compromise of host defense, and we suggest that further studies are indicated to test this hypothesis in SCD patients. , anti-C5aR IgG or isotype control IgG (30 μg) was infused 30 minutes before the mice were placed in hypoxia (7% O 2 /93% N 2 ) for 1 hour. After 1 hour of hypoxia the mice were returned to room air (reoxygenation) and stasis (no flow) was measured in the same venules after 1 and 4 hours of reoxygenation. Percent stasis was calculated and the data expressed as means ± SD. *P < 0.05, **P < 0.01 and ***P < 0.001
